GCP
RXRX icon

GSA Capital Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

GSA Capital Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.06M Buy
669,568
+643,851
+2,504% +$2.49M 0.13% 159
2025
Q4 		$105K Buy
+25,717
New +$127K 0.01% 1526
2025
Q2 		– Sell
-30,153
Closed -$160K – 2097
2025
Q1 		$160K Buy
+30,153
New +$220K 0.01% 1446
2024
Q1 		– Sell
-10,860
Closed -$107K – 1924
2023
Q4 		$107K Buy
+10,860
New +$77.4K 0.01% 1389
2023
Q1 		– Sell
-22,603
Closed -$174K – 1873
2022
Q4 		$174K Buy
+22,603
New +$222K 0.02% 1216

Other funds holding RXRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return